PMID- 35281414 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220315 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 11 IP - 2 DP - 2022 Feb TI - Analysis of prognostic and therapeutic values of drug resistance-related genes in the lung cancer microenvironment. PG - 339-357 LID - 10.21037/tcr-21-1841 [doi] AB - BACKGROUND: The interaction between cancer cells and stromal cells has a significant contribution in tumorigenesis and tumor development, and plays an anti-tumor immune effect under the regulation of drug resistance-related genes, which affects the outcome of patients. Coiled-coil domain-containing protein 73 (CCDC73), DLG associated protein 1 (DLGAP1), dermatan sulfate epimerase like (DSEL), estrogen receptor 1 (ESR1), and SEC14-like 5 (SEC14L5) were identified as drug resistance-related genes in lung cancer. However, these genes have no clear value in lung cancer in terms of expression and prognosis. METHODS: ONCOMINE, GEPIA, UALCAN, cBioPortal, GeneMANIA, STRING, and TIMER were utilized in this study. RESULTS: The transcriptional expression level of DLGAP1 was remarkably decreased in lung cancer tissues, while the transcriptional level of SEC14L5 was significantly increased. The pathological stage of lung adenocarcinoma (LUAD) was tightly correlated with the expression of SEC14L5. The lung cancer patients with high transcription level of CCDC73 gene tended to have a good prognosis. The function of drug resistance-related genes is mainly related to RNA polymerization. Our results showed that infiltration of six types of immune cells (dendritic cells, macrophages, neutrophils, B cells, CD4(+) T cells, and CD8(+) T cells) significantly correlated with the expression of these drug resistance-related genes. CONCLUSIONS: Novel screening for immunotherapy targets and prognostic biomarkers in lung cancer may draw inspiration from our results. CI - 2022 Translational Cancer Research. All rights reserved. FAU - Zhu, Liang AU - Zhu L AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Chen, Peixin AU - Chen P AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Wang, Hao AU - Wang H AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Zhao, Lishu AU - Zhao L AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Guo, Haoyue AU - Guo H AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Jiang, Minlin AU - Jiang M AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Zhao, Sha AU - Zhao S AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Li, Wei AU - Li W AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Zhu, Jun AU - Zhu J AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Yu, Jia AU - Yu J AD - School of Medicine, Tongji University, Shanghai, China. AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Dai, Jiawei AU - Dai J AD - SJTU-Yale Joint Center for Biostatistics and Data Science, Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. LA - eng PT - Journal Article PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC8904958 OTO - NOTNLM OT - Lung cancer OT - bioinformatics analysis OT - biomarkers OT - prognosis OT - tumor microenvironment COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-21-1841/coif). The authors have no conflicts of interest to declare. EDAT- 2022/03/15 06:00 MHDA- 2022/03/15 06:01 PMCR- 2022/02/01 CRDT- 2022/03/14 05:21 PHST- 2021/09/05 00:00 [received] PHST- 2021/12/22 00:00 [accepted] PHST- 2022/03/14 05:21 [entrez] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/03/15 06:01 [medline] PHST- 2022/02/01 00:00 [pmc-release] AID - tcr-11-02-339 [pii] AID - 10.21037/tcr-21-1841 [doi] PST - ppublish SO - Transl Cancer Res. 2022 Feb;11(2):339-357. doi: 10.21037/tcr-21-1841.